Form 4: Equillium Inc. Executive Stephen Connelly Reports Option Repricing and Subsequent Transactions

Stephen Connelly, Chief Scientific Officer of Equillium, Inc., reports the repricing of employee stock options and related transactions following the lapse of a holding period.

Summary

• On February 14, 2025, Stephen Connelly, the Chief Scientific Officer of Equillium, Inc., reported transactions related to employee stock options.
• The transactions involve the acquisition and disposal of derivative securities, specifically employee stock options, related to Equillium's common stock.
• The repricing of certain options, approved by the Board of Directors on August 7, 2023, became effective after a holding period that ended on February 14, 2025.
• The repricing resulted in a lower exercise price of $0.785 per share for the impacted options, based on the closing price of Equillium's common stock on August 14, 2023.
• Connelly acquired and disposed of options with varying exercise prices and expiration dates, reflecting adjustments due to the repricing.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing detailing option repricing and related transactions. It's neutral in tone and doesn't inherently indicate positive or negative sentiment, but the repricing itself could be seen as a positive move to retain talent.

Positives

• The repricing of options could potentially incentivize Connelly and other employees, aligning their interests with the company's performance.
• The lower exercise price of $0.785 may make the options more attractive to Connelly.

Management Comments

• On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023.

Industry Context

Option repricing is a common practice in the biotech industry to retain and incentivize key employees, especially when a company's stock price has declined.

Comparison to Industry Standards

• Many biotech companies use stock options as a key component of their compensation packages.
• Repricing of options is not uncommon in the industry, particularly when the stock price has fallen significantly below the original exercise price.
• Companies like Amgen, Gilead, and Biogen also utilize stock options extensively, but their specific repricing policies would need to be examined individually for comparison.

Stakeholder Impact

• Shareholders may view the option repricing as a positive or negative development, depending on their perspective on executive compensation and company performance.
• Employees holding options will likely benefit from the lower exercise price.

Key Dates

Keywords

Equillium, Stephen Connelly, Employee Stock Options, Repricing, Derivative Securities, Form 4, SEC, Chief Scientific Officer